Calithera Reports Initial Phase I Data for CB-839 in Patients with Acute Leukemias

SOUTH SAN FRANCISCO, Calif., May 21, 2015 -- Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that data from its lead, first-in-class program CB-839 will be presented at the 20^th Congress of the European Hematology Association (EHA) June 11-15, 2015, in Vienna, Austria. These preliminary data demonstrate the clinical activity, tolerability and unique mechanism of action of CB-839 in patients with acute leukemia.

"We are very encouraged by these early clinical data," said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. "While the primary objectives of this study are to determine the safety and tolerability of CB-839, we were also able to demonstrate promising clinical activity including a complete response in the bone marrow, with incomplete recovery of peripheral counts (CRi) in one patient."

Published: 21 May 2015

Written by Editor

Nasdaq Up on News Project Update

IsoRay's Cesium-131 Lung Cancer Treatment Reports 96% Success in Local Control and 100% Survival at 5 Years in High Risk Patients in Newly Published Report

Cesium-131's Outstanding Lung Cancer Results Take on Other Treatment Forms Including Stereotactic Radiation

RICHLAND, WA--( May 20, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the on-line publication of the first major peer reviewed study showing improved results using IsoRay's Cesium-131 seeds in the treatment of lung cancer.

Published: 20 May 2015

Written by Editor

AMEX Up on News Project Update

PlasmaTech Biopharmaceuticals Announces Orphan Drug and Rare Pediatric Disease Designations From FDA

Two FDA Designations for Both ABX-101 and ABX-102 for Sanfilippo Syndromes (MPS IIIA and MPS IIIB)

NEW YORK, NY--(Marketwired - May 20, 2015) - PlasmaTech Biopharmaceuticals, Inc. (PTBI), a biopharmaceutical company focused on gene therapy and plasma-based products for severe and life- threatening rare diseases announced today that the U.S. Food and Drug Administration (FDA) had granted both Orphan Drug Designation and Rare Pediatric Disease Designation for both of PlasmaTech Biopharmaceuticals' lead product candidates for the treatment of Sanfilippo Syndromes A and B.

Published: 20 May 2015

Written by Editor

Nasdaq FDA HC Decision Up on News

Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003

- Highly statistically significant 55 percent reduction in viral shedding rate with best dose -
- Company to host conference call at 9 a.m. EDT today including guest speaker Peter A. Leone, MD -

CAMBRIDGE, Mass.-- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. During the 28-day observation period immediately after completion of dosing, the best dose of 60 µg per protein / 75 µg of Matrix-M2^TM adjuvant demonstrated a highly statistically significant (p<0.0001) 55 percent reduction from baseline in the viral shedding rate, the primary endpoint of the trial and a measure of anti-viral activity. All dose combinations tested, including the successful 30 µg per protein / 50 µg of adjuvant dose from the prior Phase 1/2a trial, demonstrated a statistically significant viral shedding rate reduction versus baseline and only the lowest dose combination did not demonstrate a statistically significant reduction versus placebo.

Published: 20 May 2015

Written by Editor

Nasdaq Up on News Project Update

AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma

CAMBRIDGE, Mass.--- AVEO Oncology (AVEO) announced today that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment subsequent to disease progression on sorafenib in the Company’s Phase 3 TIVO-1 first-line RCC study, will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The Company previously reported interim median progression free survival (PFS) results of 8.4 months among the 163 patients enrolled in Study 902. Final results now show a median PFS in this setting of 11.0 months and median overall survival (OS) of 21.6 months, demonstrating the efficacy of tivozanib in a VEGF treatment refractory population.

Published: 20 May 2015

Written by Editor

Nasdaq Up on News Project Update

Calithera Biosciences Inc ( CALA )

Calithera Reports Initial Phase I Data for CB-839 in Patients with Acute Leukemias

IsoRay Inc ( ISR )

IsoRay's Cesium-131 Lung Cancer Treatment Reports 96% Success in Local Control and 100% Survival at 5 Years in High Risk Patients in Newly Published Report

PlasmaTech Biopharmaceuticals Inc ( PTBI )

PlasmaTech Biopharmaceuticals Announces Orphan Drug and Rare Pediatric Disease Designations From FDA

Genocea Biosciences Inc ( GNCA )

Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003

AVEO Oncology ( AVEO )

AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma